The Australian Professional Association for Trans Health (AusPATH) was established in 2009 and is Australia’s peak body for professionals involved in the health, rights and wellbeing of all trans people – binary and non-binary. The AusPATH membership comprises over 600 experienced professionals working across Australia.
The NHS England has recently released a Clinical Policy advising that “Puberty suppressing hormones (PSH) are not available as a routine commissioning treatment option for treatment of children and young people who have gender incongruence / gender dysphoria.” In this policy document, it is stated that a Policy Working Group commissioned by the NHS has concluded “that there is not enough evidence to support the safety or clinical effectiveness of puberty suppression hormones to make the treatment routinely available at this time”. They recommend “that access to puberty suppressing hormones for children and young people with gender incongruence/dysphoria should only be available as part of research”.
AusPATH has significant concerns about this decision by NHS England, and the negative impact that it is likely to have on young gender diverse people in the UK. It is our opinion that the NHS England is undertaking an enormous and unprecedented public health experiment on children with no safeguards.







